Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486937 | 0.88 | PTGES (0.58) | KMT2AMEN1ALOX5PTGESALDH1A1 | |
| SCHEMBL6484148 | 0.88 | PTGES (0.58) | KMT2AMEN1ALOX5PTGESALDH1A1 | |
| SCHEMBL6476997 | 0.86 | PTGS2 (0.57) | KMT2AALOX5HTR3AALDH1A1LMNA | |
| SCHEMBL6475909 | 0.85 | PTGS2 (0.46) | KMT2AMEN1ALOX5HTR3AALDH1A1 | |
| SCHEMBL6475197 | 0.81 | KMT2A (0.70) | KMT2AMEN1ALOX5ALDH1A1LMNA | |
| SCHEMBL7005247 | 0.81 | ALOX5 (0.46) | KMT2AMEN1ALOX5PTGESPTGS1 | |
| SCHEMBL6476126 | 0.77 | ALOX5 (0.47) | KMT2AALOX5PTGESPTGS1 | |
| SCHEMBL6483250 | 0.76 | PTGES (0.58) | ALOX5PTGESALDH1A1PTGS1HPGD | |
| SCHEMBL6485138 | 0.76 | PTGES (0.58) | ALOX5PTGESALDH1A1PTGS1HPGD | |
| SCHEMBL6487112 | 0.76 | PTGES (0.61) | KMT2AALOX5PTGESPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936632-B2 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | PTGS1, PTGS2, PTGER1 | KMT2A 3737/4885MEN1 4000/4885ALOX5 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.